GLP-1 receptor agonist toxicity: Difference between revisions
| Line 21: | Line 21: | ||
==Evaluation== | ==Evaluation== | ||
===Workup=== | ===Workup=== | ||
*CBC | |||
*Chemistry | |||
*LFTs + lipase | |||
===Diagnosis=== | ===Diagnosis=== | ||
*Typically a clinical diagnosis (based on history) | |||
==Management== | ==Management== | ||
Revision as of 20:30, 31 January 2024
Background
- GLP-1 receptor agonists (e.g., semaglutide) are injectable medication used for diabetes management and weight loss
- Semaglutide
- Liraglutide
- Poison control centers have reported increasing inquiries related to possible overdoses
Clinical Features
Similar to side effects normally associated with these medications, but worse:
Differential Diagnosis
Nausea and vomiting
Critical
Emergent
- Acute radiation syndrome
- Acute gastric dilation
- Adrenal insufficiency
- Appendicitis
- Bowel obstruction/ileus
- Carbon monoxide poisoning
- Cholecystitis
- CNS tumor
- Electrolyte abnormalities
- Elevated ICP
- Gastric outlet obstruction, gastric volvulus
- Hyperemesis gravidarum
- Medication related
- Pancreatitis
- Peritonitis
- Ruptured viscus
- Testicular torsion/ovarian torsion
Nonemergent
- Acute gastroenteritis
- Biliary colic
- Cannabinoid hyperemesis syndrome
- Chemotherapy
- Cyclic vomiting syndrome
- ETOH
- Gastritis
- Gastroenteritis
- Gastroparesis
- Hepatitis
- Labyrinthitis
- Migraine
- Medication related
- Motion sickness
- Narcotic withdrawal
- Thyroid
- Pregnancy
- Peptic ulcer disease
- Renal colic
- UTI
Evaluation
Workup
- CBC
- Chemistry
- LFTs + lipase
Diagnosis
- Typically a clinical diagnosis (based on history)
Management
- Symptomatic management
- Anti-nausa medications (e.g., zofran)
- Consider stopping other glucose-lowering (i.e, diabetic) medications
